AcelRx Pharmaceuticals, Inc. Appoints Howard B. Rosen as Chief Executive Officer, Effective April 1, 2016
March 29, 2016 at 05:00 pm EDT
Share
AcelRx Pharmaceuticals, Inc. announced the appointment of Howard B. Rosen as the Chief Executive Officer, effective April 1, 2016. Mr. Rosen has served as the interim CEO for AcelRx since April 1, 2015. Mr. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences, Inc. and ALZA Corporation.
More recently he was interim CEO of Pearl Therapeutics. Mr. Rosen currently serves on the Board of Directors of Alcobra Ltd. and two private biopharmaceutical companies.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
TALPHERA, INC. 
